PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune^® HPV in HPV16-Positive Head and Neck Cancer

Conference call and webcast today at 8:00 a.m. Eastern Time

Read more at globenewswire.com